Investor Overview

2018 was a strong year for our Tiara and Reducer product platforms. Both have achieved significant therapy development milestones, putting Neovasc on a stronger foundation from which to continue advancing these products commercially. We also have a clear value creation strategy for patients, employees, and investors. All of this is really good news for our outlook.

Read More >

Latest News

Neovasc's Tiara™ for Treatment of Mitral Regurgitation and Neovasc Reducer™ for Treatment of Refractory Angina Featured in Multiple Presentations at TCT 2019 Conference

> read full release

Archive >

Programs and Events

Corporate Overview Presentation

Fred Colen, CEO, Neovasc, Inc.
from the Global Investment Conference
Monday, Sept. 9, 2019

.pdf format > .pptx format >

Neovasc Featured at the MicroCap Rodeo Conference

Listen to the webcast of Fred Colen’s presentation to the first-annual gathering of microcap companies and investors in Austin, Texas by clicking here >

Financial Report Archives

2019 Financial Reports

News Release Archives

2019 News Releases

Share Information

Auditor
Grant Thornton LLP, Vancouver, BC

Legal Counsel
Blakes LLP, Vancouver, BC

Transfer Agent
Computershare, Vancouver, BC

Investor Relations
Chris Clark, Chief Financial Officer
investors@neovasc.com

To automatically receive news updates

register now